EWA
TELO icon

EverSource Wealth Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

EverSource Wealth Advisors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-379
Closed -$504 – 4518
2025
Q4 		$504 Hold
379
– – ﹤0.01% 3876
2025
Q3 		$527 Buy
379
+333
+724% +$502 ﹤0.01% 3939
2025
Q2 		$58 Sell
46
-42
-48% -$97 ﹤0.01% 4182
2025
Q1 		$284 Buy
+88
New +$385 ﹤0.01% 3612

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

EverSource Wealth Advisors's TELO Position: Q1 2026 in Review

EverSource Wealth Advisors sold out of Telomir Pharmaceuticals (TELO) in Q1 2026, closing a stake of 379 shares — an estimated $504 sold.

EverSource Wealth Advisors first reported a position in TELO in Q1 2025 and held it in 4 quarters. The position peaked at $527 in Q3 2025. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • EverSource Wealth Advisors reported no remaining Telomir Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • EverSource Wealth Advisors sold 379 Telomir Pharmaceuticals shares in Q1 2026, an estimated $504.
  • EverSource Wealth Advisors first reported a position in Telomir Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • EverSource Wealth Advisors's Telomir Pharmaceuticals position peaked at $527 in Q3 2025.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.